Drugs Made In America Acquisition Corp. (DMAA)

Drugs Made In America Acquisition Corp. is a special purpose acquisition company, or blank-check company, formed in 2024 to complete a merger, share exchange, asset acquisition or similar business combination with one or more operating businesses. It is based in New York City.

As its name suggests, the company was organized with a focus on the pharmaceutical industry, particularly businesses connected to manufacturing medicines in the United States.

The company completed its initial public offering on Nasdaq in January 2025, selling units at ten dollars each, and its ordinary shares trade under the ticker DMAA. Proceeds are held in a trust account until a business combination is completed or the funds are returned to shareholders.